Bevacizumab Liquid
NDC Package 50242-059-02

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Other Packages
    3. Frequently Asked Questions

Package Information

This product is an UNFINISHED DRUG part of the official NDC directory. Unfinished drugs include products like active ingredients some of which are used in bulk for further processing or compounding. The FDA requires a list of these drugs manufactured in a U.S. commercial distribution facility.

Bevacizumab liquids is a medication a man-made antibody (IgG1) used to treat various types of cancer. This formulation utilizes a liquid delivery system. Marketed by Genentech, Inc., this product is identified by NDC 50242-059.

Identification & Billing

NDC Package Code
50242-059-02
Package Description
300 L in 1 TANK
Product Code
50242-059
11-Digit Billing Format
50242005902

Clinical Specifications

Proprietary Name
Bevacizumab
Non-Proprietary Name
Bevacizumab
Substance Name
Bevacizumab
Dosage Form
Liquid - A dosage form consisting of a pure chemical in its liquid1 state. This dosage form term should not be applied to solutions.
Active Ingredient(s)
BEVACIZUMAB 25 g/L
Usage Information
This medication is a man-made antibody (IgG1) used to treat various types of cancer. This drug works by blocking a certain protein (vascular endothelial growth factor-VEGF) thereby decreasing the blood supply to the tumor and slowing tumor growth. This monograph is about the following bevacizumab products: bevacizumab, bevacizumab-awwb, and bevacizumab-bvzr.

Regulatory & Marketing

Labeler Name
Genentech, Inc.
Product Type
Drug For Further Processing
Marketing Category
DRUG FOR FURTHER PROCESSING - A drug (other than the bulk ingredient API) that is in an interim stage of manufacture, processing, preparation, or packaging, and not ready for human or animal use.
Start Marketing Date
02-26-2004
Listing Expiration
12-31-2026
Exclude Flag
N
Unfinished Product
Yes
Sample Package
N/A

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (50242-059). Click a package code to view its specific billing and regulatory data.

50242-059-01
120 L in 1 TANK

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 50242-059-02 identifies a specific commercial package of 300 l in 1 tank of Bevacizumab (UNFINISHED drug), drug for further processing labeled by Genentech, Inc.. This liquid is formulated for use and contains bevacizumab as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Genentech, Inc. on February 26, 2004. The current certification is valid through December 31, 2026.

What are the primary indications for this medication?

This medication is a man-made antibody (IgG1) used to treat various types of cancer. This drug works by blocking a certain protein (vascular endothelial growth factor-VEGF) thereby decreasing the blood supply to the tumor and slowing tumor growth. This monograph is about the following bevacizumab products: bevacizumab, bevacizumab-awwb, and bevacizumab-bvzr.

How is this Genentech, Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 50242005902. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
50242-059-02
11-Digit CMS (5-4-2)
50242-0059-02

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.